<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01044017</url>
  </required_header>
  <id_info>
    <org_study_id>BP22764</org_study_id>
    <secondary_id>2009-013124-23</secondary_id>
    <nct_id>NCT01044017</nct_id>
  </id_info>
  <brief_title>A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes</brief_title>
  <official_title>A Single-center, Double-blind, Randomized, Cross-over, Placebo-controlled, Single-dose Study to Investigate Glycemic Parameters of Efficacy During 24 Hours, Safety/ Tolerability and Pharmacokinetics of Two Dose Levels of RO4998452 in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo-controlled, cross-over study will evaluate the glucose
      concentration and other glycemic parameters of efficacy, and the safety and tolerability and
      pharmacokinetics of single oral doses of RO4998452 in patients with diabetes mellitus type 2.
      On 3 treatment days a week apart, patients will each receive orally one of 2 dose levels of
      RO4998452 or placebo. Anticipated time of study treatment is 3 weeks. Target sample size is
      &lt;50.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect on postprandial plasma glucose concentration</measure>
    <time_frame>Following meal 13 hours after dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean postprandial daily plasma glucose concentration (3 consecutive meals)</measure>
    <time_frame>25 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean daily blood glucose concentration, pre-meal plasma glucose concentration, plasma insulin concentration</measure>
    <time_frame>Assessments up to 25 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary glucose excretion</measure>
    <time_frame>Assessments up to 25 hours after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability: AEs, laboratory parameters</measure>
    <time_frame>AEs throughout study, laboratory assessments on 3 treatment days and on follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>single oral dose</description>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO4998452</intervention_name>
    <description>single oral doses</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, 18-75 years of age

          -  Type 2 diabetes mellitus, diagnosed for at least 3 months at screening

          -  Treatment with diet and exercise

          -  BMI between 27 and 40 kg/m2

        Exclusion Criteria:

          -  Type 1 diabetes

          -  History of ketoacidosis, hyperosmolar coma, or lactic acidosis

          -  Renal disease or renal dysfunction

          -  Evidence of significant diabetic complication

          -  Currently or within 3 months prior to screening treated with any oral or injectable
             anti-diabetic agents (exception: insulin injection in emergency situation)

          -  History of anti-diabetic triple therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Strasbourg</city>
        <zip>67064</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2009</study_first_submitted>
  <study_first_submitted_qc>January 6, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2010</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

